MIP Diagnostics
Tozaro, formerly MIP Discovery, is a biotechnology company specializing in the design and synthesis of 'smart polymers' for cell and gene therapy (CGT) bioprocessing. Leveraging a combination of molecular modeling, machine learning, and chemical synthesis, Tozaro creates custom affinity ligands tailored to specific viral vectors and applications. Their technology addresses challenges in CGT manufacturing by offering novel solutions for viral vector analytics and purification, aiming to improve efficiency, reduce costs, and increase accessibility of advanced therapies. The company's smart polymers are chemically synthesized, animal component-free, scalable, and offer gentler release conditions and higher yields compared to traditional methods. Tozaro has transitioned its focus to CGT bioprocessing, completing a £7M Series A funding round in February 2024.
MIP Diagnostics
Tozaro, formerly MIP Discovery, is a biotechnology company specializing in the design and synthesis of 'smart polymers' for cell and gene therapy (CGT) bioprocessing. Leveraging a combination of molecular modeling, machine learning, and chemical synthesis, Tozaro creates custom affinity ligands tailored to specific viral vectors and applications. Their technology addresses challenges in CGT manufacturing by offering novel solutions for viral vector analytics and purification, aiming to improve efficiency, reduce costs, and increase accessibility of advanced therapies. The company's smart polymers are chemically synthesized, animal component-free, scalable, and offer gentler release conditions and higher yields compared to traditional methods. Tozaro has transitioned its focus to CGT bioprocessing, completing a £7M Series A funding round in February 2024.